Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
Open Access
- 12 July 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (14) , 4631
Abstract
Background: Recent clinical trials have demonstrated that tafamidis (Pfizer Inc., New York, NY, USA) reduced all-cause mortality and the number of cardiovascular hospitalizations compared with placebo in patients with transthyretin cardiac amyloidosis. However, the optimal surrogate markers during tafamidis treatment remain unknown. Methods: Consecutive patients with transthyretin cardiac amyloidosis who received tafamidis in our institute between May 2019 and December 2022 were retrospectively evaluated. The prognostic impact of an increase in troponin I levels during tafamidis therapy was evaluated. Results: A total of 18 patients (median age 77 years, 84% male) were included. For 14-month tafamidis therapy on median, cardiac troponin I levels increased in five patients. The cumulative incidence of all-cause hospitalization was significantly higher in the troponin-increased group than in the others (100% versus 33%, p < 0.0001). Troponin increase was independently associated with the cumulative incidence of all-cause hospitalization with an adjusted hazard ratio of 5.14 (95% confidence interval 1.02–25.9, p = 0.048). Conclusions: The increase in cardiac troponin levels may be a reasonable surrogate marker of response to tafamidis therapy in patients with transthyretin cardiac amyloidosis.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of cardiac transthyretin amyloidosis: an updateEuropean Heart Journal, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- His Bundle Pacing: A New Frontier in the Treatment of Heart FailureArrhythmia and Electrophysiology Review, 2018
- Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)Amyloid, 2017
- Diagnostic Utility of Cardiac Troponin T Level in Patients with Cardiac AmyloidosisESC Heart Failure, 2017
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEuropean Heart Journal, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection FractionJACC: Heart Failure, 2014
- Senile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeJournal of the American Heart Association, 2013
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005